Novo Nordisk
Novo Nordisk
Novo Nordisk (pronunciation: /ˈnoʊvoʊ ˈnɔːrdɪsk/) is a multinational pharmaceutical company based in Denmark, with production facilities in eight countries, and affiliates or offices in 5 continents.
Etymology
The name "Novo Nordisk" is derived from the merger of two Danish companies, Novo Industri A/S and Nordisk Gentofte A/S. "Novo" means "new" in Latin, and "Nordisk" is Danish for "Nordic".
History
Novo Nordisk was established in 1989, following the merger of Novo Industri A/S and Nordisk Gentofte A/S. Both companies were founded in the early 20th century and were pioneers in the production of insulin for the treatment of diabetes.
Products
Novo Nordisk's product portfolio includes a range of medicines, including insulin, GLP-1 analogues for diabetes, haemophilia treatments, growth hormone therapies, and hormone replacement therapies. The company is a world leader in diabetes care and has been instrumental in developing innovative insulin delivery systems, such as insulin pens and needles.
Research and Development
Novo Nordisk invests heavily in research and development (R&D) to discover and develop new, innovative medicines. The company's R&D strategy is focused on areas where it has core competencies, such as diabetes and obesity care, haemophilia, growth disorders, and hormone replacement therapy.
Related Terms
External links
- Medical encyclopedia article on Novo Nordisk
- Wikipedia's article - Novo Nordisk
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski